PMID- 35874522
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220726
IS  - 1664-042X (Print)
IS  - 1664-042X (Electronic)
IS  - 1664-042X (Linking)
VI  - 13
DP  - 2022
TI  - A Glimpse of Inflammation and Anti-Inflammation Therapy in Diabetic Kidney 
      Disease.
PG  - 909569
LID - 10.3389/fphys.2022.909569 [doi]
LID - 909569
AB  - Diabetic kidney disease (DKD) is a common complication of diabetes mellitus and a 
      major cause of end-stage kidney disease (ESKD). The pathogenesis of DKD is very 
      complex and not completely understood. Recently, accumulated evidence from in 
      vitro and in vivo studies has demonstrated that inflammation plays an important 
      role in the pathogenesis and the development of DKD. It has been well known that 
      a variety of pro-inflammatory cytokines and related signaling pathways are 
      involved in the procession of DKD. Additionally, some anti-hyperglycemic agents 
      and mineralocorticoid receptor antagonists (MRAs) that are effective in 
      alleviating the progression of DKD have anti-inflammatory properties, which might 
      have beneficial effects on delaying the progression of DKD. However, there is 
      currently a lack of systematic overviews. In this review, we focus on the novel 
      pro-inflammatory signaling pathways in the development of DKD, including the 
      nuclear factor kappa B (NF-kappaB) signaling pathway, toll-like receptors (TLRs) and 
      myeloid differentiation primary response 88 (TLRs/MyD88) signaling pathway, 
      adenosine 5'-monophosphate-activated protein kinase (AMPK) signaling pathways, 
      inflammasome activation, mitochondrial DNA (mtDNA) release as well as 
      hypoxia-inducible factor-1(HIF-1) signaling pathway. We also discuss the related 
      anti-inflammation mechanisms of metformin, finerenone, sodium-dependent glucose 
      transporters 2 (SGLT2) inhibitors, Dipeptidyl peptidase-4 (DPP-4) inhibitors, 
      Glucagon-like peptide-1 (GLP-1) receptor agonist and traditional Chinese 
      medicines (TCM).
CI  - Copyright (c) 2022 Liu, Yang, Li, Luo, Yang, Li, Liu and Sun.
FAU - Liu, Chongbin
AU  - Liu C
AD  - Department of Nephrology, The Second Xiangya Hospital, Central South Unibersity, 
      Changsha, China.
AD  - Hunan Key Laboratory of kidney Disease and Blood Purification, Changsha, China.
FAU - Yang, Ming
AU  - Yang M
AD  - Department of Nephrology, The Second Xiangya Hospital, Central South Unibersity, 
      Changsha, China.
AD  - Hunan Key Laboratory of kidney Disease and Blood Purification, Changsha, China.
FAU - Li, Li
AU  - Li L
AD  - Department of Nephrology, The Second Xiangya Hospital, Central South Unibersity, 
      Changsha, China.
AD  - Hunan Key Laboratory of kidney Disease and Blood Purification, Changsha, China.
FAU - Luo, Shilu
AU  - Luo S
AD  - Department of Nephrology, The Second Xiangya Hospital, Central South Unibersity, 
      Changsha, China.
FAU - Yang, Jinfei
AU  - Yang J
AD  - Department of Nephrology, The Second Xiangya Hospital, Central South Unibersity, 
      Changsha, China.
FAU - Li, Chenrui
AU  - Li C
AD  - Department of Nephrology, The Second Xiangya Hospital, Central South Unibersity, 
      Changsha, China.
FAU - Liu, Huafeng
AU  - Liu H
AD  - Guangdong Provincial Key Laboratory of Autophagy and Major Chronic 
      Non-communicable Diseases & Institute of Nephrology, Affiliated Hospital of 
      Guangdong Medical University, Zhanjiang, China.
FAU - Sun, Lin
AU  - Sun L
AD  - Department of Nephrology, The Second Xiangya Hospital, Central South Unibersity, 
      Changsha, China.
AD  - Hunan Key Laboratory of kidney Disease and Blood Purification, Changsha, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220706
PL  - Switzerland
TA  - Front Physiol
JT  - Frontiers in physiology
JID - 101549006
PMC - PMC9298824
OTO - NOTNLM
OT  - anti-Inflammation
OT  - anti-hyperglycemic
OT  - diabetic kidney disease
OT  - inflammation
OT  - mineralocorticoid receptor antagonists
OT  - signaling pathway
OT  - traditional Chinese medicine
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/07/26 06:00
MHDA- 2022/07/26 06:01
PMCR- 2022/07/06
CRDT- 2022/07/25 03:54
PHST- 2022/04/04 00:00 [received]
PHST- 2022/05/18 00:00 [accepted]
PHST- 2022/07/25 03:54 [entrez]
PHST- 2022/07/26 06:00 [pubmed]
PHST- 2022/07/26 06:01 [medline]
PHST- 2022/07/06 00:00 [pmc-release]
AID - 909569 [pii]
AID - 10.3389/fphys.2022.909569 [doi]
PST - epublish
SO  - Front Physiol. 2022 Jul 6;13:909569. doi: 10.3389/fphys.2022.909569. eCollection 
      2022.